We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

63 hedge funds and large institutions have $155M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 10

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

15% more funds holding

Funds holding: 5563 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less capital invested

Capital invested by funds: $200M → $155M (-$45.3M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
29
Reduced
10
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
1
Sectoral Asset Management
Quebec, Canada
$32.4M +$1.11M +44,843 +3%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19.9M +$16.3M +658,266 +339%
BI
3
BVF Inc
California
$19.2M -$4.05M -164,131 -17%
BFA
4
BlackRock Fund Advisors
California
$15.4M +$4.19M +169,818 +35%
Primecap Management
5
Primecap Management
California
$6.21M -$1.83M -74,300 -22%
Franklin Resources
6
Franklin Resources
California
$6.01M +$521K +21,100 +9%
CCI
7
Columbus Circle Investors
$5.9M -$10.9M -443,202 -64%
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$5.83M -$280K -11,329 -4%
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.12M +$649K +26,265 +17%
BIT
10
BlackRock Institutional Trust
California
$4.07M +$2.43M +98,533 +129%
State Street
11
State Street
Massachusetts
$3.79M +$2.23M +90,289 +125%
PAMU
12
Pictet Asset Management (UK)
United Kingdom
$2.18M +$309K +12,500 +15%
Bank of America
13
Bank of America
North Carolina
$2.18M +$9.16K +371 +0.4%
Deutsche Bank
14
Deutsche Bank
Germany
$1.89M +$329K +13,340 +20%
VAM
15
Visium Asset Management
New York
$1.75M
SFM
16
Sphera Funds Management
Israel
$1.75M +$1.85M +75,000 New
TCIM
17
TIAA CREF Investment Management
New York
$1.68M +$1.47M +59,581 +470%
QBFM
18
QS Batterymarch Financial Management
New York
$1.56M +$1.65M +66,800 New
Northern Trust
19
Northern Trust
Illinois
$1.49M +$146K +5,922 +10%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.38M +$1.46M +59,200 New
EAM
21
Eventide Asset Management
Massachusetts
$1.23M
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.23M +$542K +21,937 +71%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$1.21M +$1.28M +52,036 New
TAM
24
Tocqueville Asset Management
New York
$1M +$426K +17,250 +67%
Invesco
25
Invesco
Georgia
$892K +$946K +38,317 New

OMED Hedge Fund Activity: Q2 2014 in Review

63 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2014, worth a combined $155M — down 23% from $200M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new OMED positions and 11 closed out — a net gain of 8 holders — while 29 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was Columbus Circle Investors, cutting an estimated $10.9M.

  • 63 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2014, up from 55 in Q1 2014.
  • Funds reported $155M of OncoMed Pharmaceuticals, Inc. stock for Q2 2014, down 23% quarter-over-quarter.
  • 19 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2014 and 11 closed out, a net change of +8 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $16.3M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2014 was Columbus Circle Investors, an estimated $10.9M sold.

Based on aggregated 13F filings for Q2 2014.